Univariate | Multivariate model 1 | Multivariate model 2 | |||||||
HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
DAPT at discharge | 0.46 | (0.21 to 1.00) | 0.05 | 0.43 | (0.17 to 1.08) | 0.074 | 0.24 | (0.02 to 3.52) | 0.297 |
Cilostazol at discharge | 1.06 | (0.46 to 2.46) | 0.892 | 0.93 | (0.35 to 2.46) | 0.889 | 0.29 | (0.02 to 3.62) | 0.335 |
Warfarin at discharge | 2.87 | (1.20 to 6.86) | 0.018 | 2.28 | (0.90 to 5.79) | 0.082 | 31.70 | (1.46 to 685.89) | 0.028 |
Male | 0.85 | (0.35 to 2.02) | 0.706 | 0.93 | (0.38 to 2.24) | 0.869 | 0.88 | (0.12 to 6.60) | 0.898 |
Prior lower limb revascularisation | 1.2 | (0.54 to 2.67) | 0.654 | 1.24 | (0.55 to 2.80) | 0.602 | 2.44 | (0.31 to 19.50) | 0.399 |
Prior coronary revascularisation | 1.14 | (0.52 to 2.50) | 0.745 | 1.44 | (0.61 to 3.38) | 0.407 | 1.64 | (0.23 to 11.85) | 0.622 |
Severe calcified lesion | 0.69 | (0.45 to 1.07) | 0.095 | 0.68 | (0.44 to 1.05) | 0.084 | 0.44 | (0.16 to 1.23) | 0.118 |
Model 1: adjusted for DAPT at discharge, cilostazol at discharge, warfarin at discharge, male, prior lower limb revascularisation, prior coronary revascularisation and severe calcified lesion.
Model 2: shared-frailty model with each institution and ID as a random intercept, adjusted for variable in model 1.
DAPT, dual antiplatelet therapy; TLR, target lesion revascularisation.